Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Pemafibrate
As low as
135
CHF
CHF 135.00
In stock
Only %1 left
CDX-P0721-M01010 mgCHF 135.00
CDX-P0721-M05050 mgCHF 464.00
NEW
| Product Details | |
|---|---|
| Synonyms | K877; (R)-K 13675; CS-2768 |
| Product Type | Chemical |
| Properties | |
| Formula | C28H30N2O6 |
| MW | 490.56 |
| CAS | 848259-27-8 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (NMR) |
| Appearance | White to yellow solid. |
| Solubility | Soluble in DMSO (20mg/ml). Insoluble in water. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ZHKNLJLMDFQVHJ-RUZDIDTESA-N |
| Smiles | CC[C@H](C(O)=O)OC1=CC(CN(C2=NC3=C(C=CC=C3)O2)CCCOC4=CC=C(OC)C=C4)=CC=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Pemafibrate is a peroxisome proliferator-activated receptor α agonist (PPARα EC50 = 1nM for transcriptional activity). Pemafibrate is selective for PPARα over PPARδ and PPARγ (EC50 = 2300 and 1000nM, respectively). PPARα is a transcription factor that is essential for regulation of lipid homeostasis and glucose metabolism and has been implicated in inflammation. Pemafibrate was associated with the inhibition of inflammatory responses without affecting cell proliferation or angiogenesis, and subsequently may induce an anti-atherosclerotic effect.
Product References
(1) K. Kitajima, et al.; Atheroscl. 203, 75 (2009) | (2) N. Hennuyer, et al.; Atheroscl. 249, 200 (2016) | (3) Y. Honda, et al.; Sci. Rep. 7, 42477 (2017) | (4) N. Ferri, et al.; Expert. Opin. Investig. Drugs 26, 593 (2017) | (5) J.C. Fruchart; Cardiovasc. Diabetol. 16, 124 (2017) | (6) Y. Yamamoto, et al.; Biochem. Biophys. Res. Commun. 499, 239 (2018) | (7) J.C. Fruchart & R.D. Santos; Curr. Opin. Lipidol. 30, 419 (2019) | (8) Y. Sasaki, et al.; Sci. Rep. 10, 7818 (2020)